Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury

BACKGROUND: Recently, glucagon-like peptide-1 (GLP-1)-based therapy, including dipeptidyl peptidase-4 (DPP-4) inhibitors and GLP-1 receptor agonists, has emerged as one of the most popular anti-diabetic therapies. Furthermore, GLP-1-based therapy has attracted increased attention not only for its gl...

Descripción completa

Detalles Bibliográficos
Autores principales: Terawaki, Yuichi, Nomiyama, Takashi, Kawanami, Takako, Hamaguchi, Yuriko, Takahashi, Hiroyuki, Tanaka, Tomoko, Murase, Kunitaka, Nagaishi, Ryoko, Tanabe, Makito, Yanase, Toshihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240860/
https://www.ncbi.nlm.nih.gov/pubmed/25407968
http://dx.doi.org/10.1186/s12933-014-0154-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4240860/
https://www.ncbi.nlm.nih.gov/pubmed/25407968
http://dx.doi.org/10.1186/s12933-014-0154-3

Ejemplares similares